durogesic 25 µg/1 hr transdermalni flaster
inpharm co. d.o.o. banja luka - fentanil - transdermalni flaster - 25 µg/1 hr - 1 transdermalni flaster sadrži: 4,2 mg/10,5 cm2 (25 mcg/h) fentanil
durogesic 50 µg/1 hr transdermalni flaster
inpharm co. d.o.o. banja luka - fentanil - transdermalni flaster - 50 µg/1 hr - 1 transdermalni flaster sadrži: 8,4 mg/21 cm2 (50 mcg/h) fentanil
durogesic 100 µg/1 hr transdermalni flaster
inpharm co. d.o.o. banja luka - fentanil - transdermalni flaster - 100 µg/1 hr - 1 transdermalni flaster sadrži: 16,8 mg/42 cm2 (100 mcg/h) fentanil
protopic
leo pharma a/s - takrolimus - dermatitis, atopic - ostali dermatološki pripravci - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. javlja četiri ili više puta godišnje), koji su imali početni odgovor za najviše šest tjedana terapije, dva puta dnevno masti tacrolimus (mjesta očistili, gotovo izbrisani ili slabo utječe).
piperacillin/tazobactam panpharma 4 g/1 viala+ 0.5 g/1 viala prašak za rastvor za infuziju
sanmed d.o.o. banja luka - piperacilin, tazobaktam - prašak za rastvor za infuziju - 4 g/1 viala+ 0.5 g/1 viala - 1 bočica sa praškom za rastvor za infuziju sadrži: 4,0 g piperacilin; 0,5 g tazobactam
bromhexine sopharma 8 mg/1 tableta tableta
unifarm d.o.o. lukavac - bromheksin - tableta - 8 mg/1 tableta - 1 tableta sadrži: 8 mg bromheksinhidrohlorid a
bromhexine sopharma 4 mg/5 ml sirup
unifarm d.o.o. - bromheksin - sirup - 4 mg/5 ml - 5 ml sirupa sadrži: 4 mg bromheksinhidrohlorida
vorikonazol accordpharma 200 mg prašak za otopinu za infuziju
accord healthcare polska sp. z o.o., ul. tasmowa 7, mazowieckie, varšava, poljska - voriconazolum - prašak za otopinu za infuziju - 200 mg - urbroj: jedna bočica sadrži 200 mg vorikonazola
aripiprazole mylan pharma (previously aripiprazole pharmathen)
mylan pharmaceuticals limited - aripiprazola - schizophrenia; bipolar disorder - psycholeptics - aripiprazol mylan pharma je indiciran za liječenje shizofrenije kod odraslih i adolescenata starijih od 15 godina. Арипипразол Майлана pharma je indiciran za liječenje od umjerenih do teških maničnih epizoda kada je bipolarni poremećaj poremećaj i za prevenciju novog manic epizoda kod odraslih, koji su doživjeli pretežno manične epizode, a čiji je manične epizode odgovorio na арипипразол u liječenju. Арипипразол Майлана pharma je indiciran za liječenje do 12 tjedana umjerenih i teških maničnih epizoda u bipolarni poremećaj kod adolescenata u dobi od 13 godina i stariji.
clopidogrel viatris (previously clopidogrel taw pharma)
viatris limited - klopidogrel besilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotska sredstva - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). porastom segmenta st akutni infarkt miokarda, u kombinaciji s ask u liječenju pacijenata koji imaju pravo na thrombolytic terapije. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. za više informacija, molimo pogledajte odjeljak 5.